argenx SE – (ARGX) Forecasted to Post FY2018 Earnings of ($1.91) Per Share

argenx SE – (NASDAQ:ARGX) – Analysts at Piper Jaffray Companies increased their FY2018 EPS estimates for shares of argenx in a report released on Thursday, October 25th. Piper Jaffray Companies analyst E. Tenthoff now expects that the company will post earnings of ($1.91) per share for the year, up from their prior estimate of ($2.15). Piper Jaffray Companies currently has a “Overweight” rating and a $154.00 price objective on the stock. Piper Jaffray Companies also issued estimates for argenx’s Q4 2018 earnings at ($0.63) EPS, Q1 2019 earnings at ($0.62) EPS, Q2 2019 earnings at ($0.66) EPS, Q3 2019 earnings at ($0.67) EPS, Q4 2019 earnings at ($0.75) EPS and FY2019 earnings at ($2.71) EPS.

Several other brokerages have also recently weighed in on ARGX. Stifel Nicolaus began coverage on argenx in a report on Thursday, September 13th. They set a “buy” rating and a $139.00 target price on the stock. Evercore ISI began coverage on argenx in a report on Monday, October 15th. They set an “outperform” rating and a $110.00 target price on the stock. JMP Securities boosted their target price on argenx to $150.00 and gave the stock an “outperform” rating in a report on Monday, September 17th. Wedbush boosted their target price on argenx from $114.00 to $121.00 and gave the stock a “positive” rating in a report on Tuesday, September 18th. Finally, SunTrust Banks boosted their target price on argenx to $132.00 and gave the stock an “in-line” rating in a report on Tuesday, September 18th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $130.50.



ARGX stock opened at $73.95 on Monday. argenx has a 12-month low of $22.21 and a 12-month high of $103.00. The stock has a market capitalization of $2.38 billion, a P/E ratio of -52.82 and a beta of 2.38.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Granahan Investment Management Inc. MA lifted its holdings in argenx by 102.6% in the second quarter. Granahan Investment Management Inc. MA now owns 95,419 shares of the company’s stock valued at $7,906,000 after acquiring an additional 48,319 shares during the last quarter. Redmile Group LLC lifted its holdings in argenx by 182.2% in the second quarter. Redmile Group LLC now owns 673,300 shares of the company’s stock valued at $55,790,000 after acquiring an additional 434,700 shares during the last quarter. United Services Automobile Association lifted its holdings in argenx by 78.9% in the second quarter. United Services Automobile Association now owns 32,200 shares of the company’s stock valued at $2,668,000 after acquiring an additional 14,200 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in argenx by 18.3% in the second quarter. Point72 Asset Management L.P. now owns 70,978 shares of the company’s stock valued at $5,881,000 after acquiring an additional 10,978 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in argenx by 1.0% in the second quarter. Janus Henderson Group PLC now owns 440,579 shares of the company’s stock valued at $36,506,000 after acquiring an additional 4,457 shares during the last quarter. Hedge funds and other institutional investors own 55.95% of the company’s stock.

argenx Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

See Also: Fundamental Analysis – How It Helps Investors

Earnings History and Estimates for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply